Mercedes
Garayoa Berrueta
Investigadora desde 2011
Hospital Universitario Marqués de Valdecilla
Santander, EspañaPublicaciones en colaboración con investigadores/as de Hospital Universitario Marqués de Valdecilla (6)
2021
-
Bone marrow mesenchymal stromal cells in multiple myeloma: Their role as active contributors to myeloma progression
Cancers, Vol. 13, Núm. 11
-
Stroma-Mediated Resistance to S63845 and Venetoclax through MCL-1 and BCL-2 Expression Changes Induced by miR-193b-3p and miR-21-5p Dysregulation in Multiple Myeloma
Cells, Vol. 10, Núm. 3
2020
-
Filanesib for the treatment of multiple myeloma
Expert Opinion on Investigational Drugs, Vol. 29, Núm. 1, pp. 5-14
-
Preclinical evaluation of the simultaneous inhibition of MCL-1 and BCL-2 with the combination of S63845 and venetoclax in multiple myeloma
Haematologica
-
Protein translation inhibition is involved in the activity of the pan-pim kinase inhibitor pim447 in combination with pomalidomide-dexamethasone in multiple myeloma
Cancers, Vol. 12, Núm. 10, pp. 1-20
2019
-
Biological Background of Resistance to Current Standards of Care in Multiple Myeloma
Cells, Vol. 8, Núm. 11